Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Inflammatory bowel disease

Inflammatory bowel disease may be linked to increased risk of dementia

Research suggests that people who have inflammatory bowel disease are more likely to develop dementia later in life, and at a younger age, than people who do not.

Old man with IBD


Researchers compared 1,742 patients aged 45 years or older who were diagnosed with IBD without prior dementia, against 17,420 controls

People with inflammatory bowel disease (IBD) have a significantly higher risk of developing dementia later in life, a study in Gut has suggested (23 June 2020)[1].

In a population-based cohort study, researchers performed a comparative analysis of 1,742 patients diagnosed with IBD between 1998 and 2011, aged 45 years or older and without prior dementia, against 17,420 controls.

During the follow-up period (from enrolment to 31 December 2013 or death) the researchers found that overall incidence of dementia in the IBD cohort was 5.5% compared with 1.4% in the control group. People with IBD were also diagnosed with dementia at a younger age, on average, than the control group (76.2 years vs. 83.5 years).

They calculated that the hazard ratio of developing dementia among patients with IBD was 2.54 (95% confidence interval 1.91–3.37). Among dementia types, the risk of developing Alzheimer’s disease was the greatest.

The researchers said the findings suggest the roles of the gut-brain axis and chronic inflammation in progressive neurocognitive degeneration. They highlighted the need for further research to investigate the relationship between IBD and dementia.

“Vigilance and education for dementia among elderly patients with IBD may improve early intervention to slow cognitive decline and improve quality of life,” they added.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20208113

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Pathology and Therapeutics for Pharmacists

    Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

    £54.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • International Research in Healthcare

    International Research in Healthcare

    Guidance for students or researchers undertaking a multi-centre research project in health services, medicines use and professional practice.

    £38.00Buy now
  • Biological Therapeutics

    Biological Therapeutics

    An introduction to the treatment of disease using biological medicines derived from living plant and animal tissues.

    £33.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.